Yea, it's tough to watch, especially when others are moving up. After the big move earlier this month, a new base is needed for the next leg up. The stronger the base, usually, will determine the strength of the next move higher. So I would imagine another week or two to consolidate with maybe a minor edge higher, then this should start to move higher and if the last quarter numbers are good,( first rec. sales) we shareholders should see the move up and beyond that 52 week high of $2.57 US. Once the 2nd quarter numbers 2019 are released in August there should be a solid 10K to 15K of product sold in the first 2 quarters. I would imagine that 8 Capital's price of $4.50 Canadian or around 3.40 US will be realized. Based on this math: Using the 10K lower end of the production, I have done the math.
10,000 X 1000 grams = 10,000,000. grams at an average at 5/gram (factors wholesale and medical pricing mixed) Sold between the months of Jan.-June, and using just the current production capacity of 136,000 Sq. Ft. that is already licensed, That's 50 million in revenue just for the first 2 Quarters. I am anticipating full production by sometime in Q2. So by the fourth quarter there could be at least double that based on full capacity of roughly 50k when Srathroy is completely built out. So there is another 100 Million. 2019 = 150,000,000 in revs is my prediction. This factors in that in 2019 not all the 50k will be available. More like 30k is my bet. I would imagine 30% would be the profit margin, even though Weed MD has about the best run rate of all LPS. so bottom line 150 million X .30 = 45 million. X that by a very conservative multiple of 15 and you get. 45 million / 120 million shares (warrants) you get .37/share X
15 = 5.62/share. That is exactly what i predict for WEED MD by Dec. 2019. ALL IMO GLTA>
